



Israel
Cancer
Research
Fund

Impact
Statement
2022

The answer
to cancer
is research



Dear Friends,



David Abramson
President, ICRF
International

2022 has been a *mixed* year for all of us. On the one hand, we have seen a return to in-person activities and are slowly able to reestablish our pre-COVID lives. Friends and families are reuniting and there is real joy in coming together again as communities. On the other, the world has experienced greater economic, social, and political turbulence. It truly has been a *mixed* year. But not so at ICRF. We have resolutely kept up our fight to eradicate cancer through cutting-edge research and refuse to accept any result other than success.

With that in mind, we want to share some of ICRF's noteworthy achievements in 2022:

- We have renewed our partnerships with the **Cancer Research Institute (CRI)** and **Conquer Cancer (The ASCO Foundation)**. We're thrilled about the work of **Dr. Orit Kaidar-Person**, who in a co-funded project between ICRF and Conquer Cancer, will identify high-risk areas for cancer reoccurrence in residual breast tissue after mastectomy and reconstruction. We are also excited about the possibilities for **Dr. Yifat Merbl's** research to improve the efficacy of immunotherapy for treatment of melanoma, co-funded through our partnership with CRI.
- ICRF is very proud to have given two new **ICRF-Glazer Foundation Professorship Grants**. These five-year grants will allow the recipients to pursue their long-term research. **Dr. Rotem Karni** will be investigating RNA-based cancer therapies and **Dr. Shai Izraeli** will be working with new therapies that will, hopefully, cure every child with leukemia (p. 5). Yes... a CURE for ALL childhood leukemia!
- The incredibly dedicated ICRF scientists in Israel continue to be at the forefront of cancer research: **Dr. Assaf Zinger** is developing nanotechnology to inhibit tumor propagation in triple-negative breast cancer and **Dr. Ronit Ilouz** is working toward novel treatments for prostate cancer by inhibiting enzymes that regulate cell growth without causing unwanted side effects (p. 5).
- Our scientists have also announced some exceptional breakthroughs this year — from **Dr. Rony Dahan's** improvement of an immunotherapy drug previously considered too toxic for broad use to **Dr. Jacob Hanna's** creation of a synthetic mouse embryo with a beating heart using only skin cells, which has the potential to regenerate living tissue removed due to cancer or damaged by cancer treatment (p. 8).

ICRF's mission is to support the best and brightest scientists conducting ground-breaking cancer research in Israel. Your gift will help bring us closer to our goal of ending the suffering caused by cancer. The answer to cancer is research!



Bryna Goldberg
Chair, ICRF
International

These are just a few achievements of the **83 cancer research grants** that ICRF is currently sponsoring. None of this could have happened without your support. Everyone knows someone who has suffered from cancer. It is a modern plague that impacts millions of lives every day. ICRF's mission is to end the suffering caused by cancer, and the best way to do that is to fund the research that is making strides every day toward earlier diagnoses, better treatments, and, ultimately, cures. Please continue to support ICRF in funding this research.

Finally, on a personal note, we are so happy that, after two years of "virtual meetings," we have finally been able to be with you in person once again. From Los Angeles to New York, from Canada to Israel, and all the chapters in between, being together with you, sharing our love and mutual commitment to ICRF, has been the highlight of 2022 for us.

Together in partnership,



Beryl P. Chernov
ICRF National
Executive Director

David Abramson
President,
ICRF International

Bryna Goldberg
Chair,
ICRF International

Beryl P. Chernov
ICRF National
Executive Director

Making an Impact

Over
2,700
grants
funded
to date

83
cancer
research
projects
funded
2022-
2023

- 4 Acceleration Grants
- 9 Research Professorship Grants
- 14 Research Career Development Awards
- 35 Project Grants
- 5 Postdoctoral Fellowships
- 6 Collaborative Research Partnership Grants
- 9 Special Funding Initiatives
- 1 Clinical Research Career Development Award

Among the areas of cancer research being supported are studies in blood, bone, brain, breast, colorectal, lung, ovarian, pediatric, and skin cancers, as well as drug development and chemoresistance, targeted therapy and immunotherapy, and cancer stem cells.

Collaborative Partnership Grants

ICRF-Cancer Research Institute (CRI) Clinic and Laboratory Integration Program (CLIP) Grant

\$200,000 over a two-year period to support established Israeli investigators who are studying critical topics at the intersection of laboratory and clinical research in immuno-oncology.

ICRF-City of Hope Jacki & Bruce Barron Cancer Research Scholars' Program Grants

\$440,000 over a two-year period to support collaborative science conducted by co-investigators, one at City of Hope in the U.S. and the other in Israel, in order to advance our understanding of cancer and develop life-saving therapies, novel diagnostic approaches or prevention strategies.

ICRF-Conquer Cancer (The ASCO Foundation) Career Development Award

\$200,000 over a three-year period to support an Israeli early-career clinical investigator to establish an independent clinical cancer research program.

Over **\$87 million** in funding to date awarded for groundbreaking cancer research conducted at every leading institution across Israel.



ICRF-Israel Ministry of Science and Technology Geshar Grant for Academic Excellence in the Field of Cancer Research

NIS 600,000 over a three-year period to support outstanding Israeli cancer scientists living abroad who wish to return to Israel to develop an independent research program.

Max Ritvo, Alan Slifka & Desiree Dato Fund for Fusion-Oncoprotein Cancers and Metastasis Grants – A Partnership Between ICRF, The Samuel Waxman Cancer Research Foundation, and The Alan B. Slifka Foundation

\$250,000 over a two-year period to support collaborative science conducted by co-investigators based in the U.S. and Israel, with a focus on cancers driven by fusion oncoproteins in Ewing's sarcoma or metastatic cancer.



Israel Ministry of Science & Technology



Named Grants

Research Professorship Grants*

- The Harvey and Gloria Kaylie Foundation Research Professorship Grant
- ICRF – Glazer Foundation Research Professorship Grant
- ICRF – Nikoh Foundation Research Professorship Grant
- The Mark z"l & Zita z"l Bernstein Research Professorship Grant

Project Grants*

- Dr. Jerry Gross Memorial Project Grant
- The Dr. Peter J. Stambrook Award in Cancer Medicine
- Dubi Fishel Fund for Pancreatic Cancer Research
- The Eve Wald Memorial Project Grant
- ICRF – The Mark Foundation for Cancer Research Project Grant
- The "Larger than Life" Pediatric Project Grant
- The Omer Ashkenazi Memorial Project Grant

Research Career Development Awards*

- Dr. Jerry Gross Memorial Research Career Development Award
- The David and Janet Polak Foundation Research Career Development Award
- ICRF – Scott R. MacKenzie Foundation Research Career Development Award
- ICRF – Ziontz Foundation Research Career Development Award
- The Marjorie B. Cohen Memorial Research Career Development Award

Postdoctoral Fellowships*

- The Cheri Meyer Memorial Award and Dr. Leo Gordon and Team Honorary Award
- Alexander Family Grant for Women's Cancers

* See p. 10 for more information about each grant.

Special Initiatives

Brause Family Initiative for Quality of Life

\$275,000 over a three-year period to support established Israeli investigators studying cancer treatment related to pain, side effects, and emotional problems experienced by cancer patients in order to maintain the best possible quality of life, with an emphasis on non-opioid solutions.

Len & Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers

\$315,000 over a three-year period to support established Israeli investigators studying the biology, diagnosis, treatment, or prevention of ovarian and/or uterine/MMMT cancers.

Barbara S. Goodman Endowed Research Career Development Award for Pancreatic Cancer

\$148,500 over a three-year period to support a young Israeli scientist embarking on an independent research career with a particular focus on the biology, diagnosis, treatment, supportive care, and/or prevention of pancreatic cancer.

Beverly Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers

\$315,000 over a three-year period to support established Israeli investigators studying the diagnosis and/or treatment of ovarian and female reproductive system cancers.

Selecting the Best Science



Nancy Maizels, PhD,
Chair, ICRF International
Scientific Council; Chair,
ICRF Scientific Review
Panel C; Professor of
Immunology and
Biochemistry Emerita,
University of
Washington School of
Medicine, Seattle

The mission of ICRF is to fund the very best cancer research conducted by scientists at leading institutions throughout Israel. The scientific peer review process is central to this mission. It's my honor to serve as the Chair of the ICRF International Scientific Council (ISC), a group of scientists and physician-scientists who provide scientific leadership to ICRF and oversee the peer review process to ensure that it is both transparent and fair.

The first step in peer review is detailed evaluation of each proposal by one of the three Scientific Review Panels (SRPs). SRP members are leading U.S. and Canadian scientists from all fields of cancer research, who generously agree to commit their time to provide rigorous and detailed written reviews of six to eight proposals each year. SRPs meet in March to critically discuss proposals and assign priority scores based on the significance and potential impact of the research for cancer, the qualifications of the applicant, the available infrastructure and intellectual environment, and the budget. Scores from all panels are merged into a priority list that identifies top candidates for funding. The next step is that the ISC evaluates the priority list and makes formal recommendations to the ICRF International Board of Trustees. Finally, the Board allocates funds. This multi-step process — SRP to ISC to Board — ensures that the review is transparent and objective, and that ICRF supports research of the highest quality and greatest potential impact.

I first became involved with ICRF in 2007, when I was invited to join a Scientific Review Panel. During my career I've reviewed many papers and grant applications from top U.S. and international investigators, but among the small pile of ICRF applications I was assigned, a few went far beyond anything I had seen in other contexts.

The very best applications to ICRF are characterized by their creativity, their focus on highly significant problems, and the relatively modest budgets they require to accomplish their goals. ICRF support makes an enormous difference to the Israeli scientists that we fund. It's an honor to be part of the process that identifies the top research and brings it forward for funding, and it's a pleasure to work with the many dedicated folks at ICRF who support this effort.

ICRF Peer Review Process

ICRF's peer review process is highly regarded throughout the scientific community for being thorough, transparent, and fair. It is based on the application process used by the National Institutes of Health (NIH).

1 Israeli Scientists Submit Grant Applications



Israeli scientists, based in Israel, submit comprehensive descriptions of their proposed cancer-related research in December.

2 Scientific Review Panels (SRPs) Evaluate Each Proposal



Applications are assigned to one of three scientific review panels. Two reviewers from the assigned panel each provide a detailed evaluation based on:

- Potential to advance diagnosis, treatment, or prevention of cancer
- Innovation, scientific merit, and originality
- Qualifications of the applicant
- Research facilities and intellectual environment
- Budget

3 SRPs Make Recommendations



The SRPs meet annually in March. The U.S. and Canadian experts on the SRPs discuss the applications and assign an overall rating to each one. Funding is based on these ratings.

4 International Scientific Council (ISC) Establishes Funding Priority



ICRF scientific policy is overseen by the ISC, composed of eminent U.S., Canadian, and Israeli cancer researchers. The ISC evaluates the applications based on scores from the SRPs and makes recommendations for funding to the ICRF International Board of Trustees.

5 Board Allocates Resources



ICRF's International Board of Trustees allocates available resources; funding for each grant is continued only if the required progress reports are satisfactory.

83 cancer research projects funded in 2022-2023

Spotlight on the Scientists



"ICRF has been instrumental...in our internationally-acclaimed discoveries of childhood leukemias driven by abnormal signaling, many of which have a bad prognosis, but also have a possibility for a cure with novel biological therapies."

Shai Izraeli, MD

*Schneider Children's Medical Center of Israel and
Tel Aviv University, Sackler School of Medicine
ICRF - Glazer Foundation Research Professorship Grant*



"Cancer research is a very competitive field with limited resources. This prestigious ICRF Research Professorship grant will enable me to conduct innovative, high-impact research, which is usually high-risk and not easily funded. My work focuses on a vital step in gene expression, called RNA splicing, which is damaged or uncontrolled in many diseases, especially cancer. The advent of mRNA vaccines during the pandemic and recent approval of RNA-based therapies for genetic disorders showed the world the power of RNA therapeutics; but to date, no such therapies exist for cancer. My goal is to develop RNA-based cancer treatments."

Rotem Karni, PhD

*Hebrew University-Hadassah Medical School
ICRF - Glazer Foundation Research Professorship Grant*



"Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with the shortest survival time and the highest relapse rate. My lab develops nanoparticles to mimic the natural ways in which white blood cells target cancer and inflammation. This ICRF RCDA will make a tremendous impact on our work to develop new, biomimetic nanotechnology that will inhibit and limit tumor propagation. Together we can fight cancer with research."

Assaf Zinger, PhD

*Technion, Israel Institute of Technology
The David and Jane Polak Foundation Research Career
Development Award*



"I am a junior faculty member in the medical school at Bar-Ilan University and was thrilled to learn of my selection for the ICRF RCDA. I am currently leading a team that includes graduate students and senior scientists working extensively to identify the molecular and cellular mechanisms that drive prostate cancer cells. It is my mission to develop a cure for prostate cancer and this grant will enable us to focus on research challenges."

Ronit Ilouz, PhD

*Bar-Ilan University
ICRF Research Career Development Award Recipient*

Over **2,700** grants funded to date

Spotlight on the Scientists (continued)



“Driven by a passion to understand complex biological systems, and a conviction that discovering new biology will eventually lead to new therapies, I am excited and humbled to accept this vote of confidence in my research by ICRF. We will use experimental models as well as analyze samples from patients with inflammation-driven colon cancer, in order to gain a deeper understanding of how inflammation develops into cancer, and to develop new therapies for inflammatory bowel disease (IBD) patients at risk for colitis-associated colon cancer. I am looking forward to continuing this exciting journey of discovery.”

Ruth Scherz-Shouval, PhD

*Weizmann Institute of Science
ICRF Project Grant Recipient*



“I have been involved in cancer research from the earliest stages of my career and I continue to be passionately committed to advancing the knowledge and discoveries that will lead to better treatment. Cancer mortality is almost exclusively a result of tumor metastasis. This important ICRF grant will enable my lab to continue to study the molecular pathways that underly the development of breast cancer that has metastasized to the bone, in order to design novel therapies to efficiently inhibit this process.”

Neta Erez, PhD

*Tel Aviv University
ICRF Project Grant Recipient*



“Ovarian cancer is often a deadly disease, mostly due to its late diagnosis, when the disease is incurable. Our mouse models, and our efforts focused on prevention, could potentially reduce the number of women suffering from the lethal consequences of this disease, and the number of women suffering from the emotional burden of cancer diagnosis. This significant grant will be instrumental in our endeavors to understand how ovarian cancer starts, and whether we can prevent it.”

Ruth Perets, MD, PhD

*Rambam Health Care Campus
ICRF Beverley Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers Grant Recipient*



“ICRF is crucial for our overall goal of developing novel, non-addictive painkillers. To achieve this critical goal, we need to conduct cutting-edge research that, unfortunately, is expensive. The funding from ICRF enables us to pay stipends for talented students that perform the analysis and to buy the necessary equipment and materials for this study.”

Avi Priel, PhD

*Hebrew University of Jerusalem
ICRF Brause Family Initiative for Quality of Life Grant Recipient*

Stories of Hope

After my diagnosis 21 years ago, a leukemia specialist said, "Let's try you on Gleevec®." Following my next bone marrow biopsy just 56 days later, I was handed a piece of paper that read: "No evidence...of the Philadelphia Chromosome*."

— **Rabbi Andrew Sklarz**

2016 ICRF Connecticut Heroes of Hope Honoree



My diagnosis at age 35 with triple negative breast cancer was delivered with grim survival statistics but thanks to cutting-edge research and trials, I'm alive today...and cancer free for 17 years! I will forever be grateful for the tremendous gift of watching my then five-year-old daughter grow up. Thanks to all the amazing doctors, nurses, researchers, donors, friends, and family who made this possible.

— **Laura Alexander**

Friend of ICRF

Dealing with a diagnosis of invasive ductal carcinoma at age 34 with a young baby in the middle of a pandemic has negatively impacted so many aspects of my life, both physically and emotionally. Knowing that organizations like ICRF exist to combat cancer with groundbreaking research gives me hope and reassurance for my future.

— **Robyn Grosshandler**

Cancer Advocate



As a board member of ICRF, I know how important our grants are to Israeli scientists who are making groundbreaking and life-saving discoveries.

As a woman with a personal history of breast cancer, as well as friends and family members affected by cancer, I can't stress enough the importance of regular screenings. I am comforted to know that ICRF-funded research has a significant impact on cancer treatments, outcomes, and survival rates.

— **Laurie Sheff**

Toronto ICRF Board Member, 2021 Myra York Woman of Action Community Award Honoree

* The Philadelphia Chromosome is a key indicator of leukemia. Its molecular structure was identified by ICRF-funded researcher Dr. Eli Canaani, which led the way to Gleevec's development.

Chapter Highlights



Chicago



New York



Connecticut



Toronto



Montreal



Israel



ICRF in the News

Ronit Satchi-Fainaro, PhD / Tel Aviv University / Research Professorship Grant
How Gene Editing Can Help Treat Skin Cancer
Newsweek | Brian Blum, Zenger News | October 2022

Ravid Straussman, MD, PhD / Weizmann Institute of Science / ICRF-City of Hope Jacki & Bruce Barron Cancer Research Scholars' Program
A New Approach to Spotting Tumors: Look for Their Microbes
The New York Times | Carl Zimmer | September 2022

Jacob Hanna, MD, PhD / Weizmann Institute of Science / ICRF - Nikoh Foundation Research Professorship Grant
Using Only Skin Cells, Israeli Lab Makes Synthetic Mouse Embryos with Beating Hearts
The Times of Israel | Nathan Jeffay | August 2022


Rony Dahan, PhD / Weizmann Institute of Science / Project Grant
Israeli Lab Says It Has Made Safe a Powerful — But Toxic — Cancer Treatment
The Times of Israel | Nathan Jeffay | March 2022

Ziv Shulman, PhD / Weizmann Institute of Science / Beverly Librach Abshez Initiative for Ovarian and Female Reproductive System Cancers
Israeli Researchers Find a New, Natural Weapon for Fighting Cancer
The Jerusalem Post | Jerusalem Post Staff | March 2022

Financials

Annual Research Funding


Millions of Dollars



ICRF Funding Totals Per Institution 1990/1991—2021/2022

Institution	Total
Ariel University	\$205,000
Assaf-Harofeh Medical Center	\$150,000
Bar-Ilan University	\$4,240,667
Ben-Gurion University	\$2,370,500
Carmel Hospital	\$319,000
Chaim Sheba Medical Center	\$3,592,500
Hadassah University Hospital	\$2,824,863
Hebrew University	\$17,111,800
Kaplan Hospital	\$85,500
MIGAL - Galilee Technology Center	\$370,000
National Institute of Oceanography	\$105,000
Rabin Medical Center, Beilinson and Golda Campuses	\$528,500
Rambam Medical Center	\$1,720,000
Schneider Children's Medical Center	\$200,000
Shaare Zedek Medical Center	\$882,000
Technion, Israel Institute of Technology	\$9,493,500
Tel-Aviv Sourasky Medical Center	\$596,666
Tel-Aviv University	\$10,759,000
University of Haifa	\$105,000
Volcani Institute	\$30,000
Weizmann Institute of Science	\$12,875,900
Western Galilee Medical Center	\$105,000
Total	\$68,670,396

Sources of Income



Please be advised that amounts reflect no bias and have not been allocated per institution, but impartially to the scientists who scored the highest in ICRF's fully-objective, grant application peer-review process.

A Legacy of Generosity

Planned Giving

With a planned gift to the Israel Cancer Research Fund, you can leave a philanthropic legacy that will help those touched by cancer — now and for years to come. Whether you would like to put your donation to work today or in the future, there are a variety of opportunities for making a legacy commitment. Visit icrfonline.org/planned-giving to learn how you can create a lasting impact on the future of cancer research.

ICRF Donor Recognition Park in Tel Aviv

ICRF Donor Recognition Park in Tel Aviv, a 4.5-acre oasis of greenery and tranquility, maintained by the Tel Aviv municipality, exists as a living monument to the memory of loved ones throughout the world lost to cancer. The park also provides a permanent place of recognition for ICRF's generous benefactors.



The Donor Wall, located at the heart of the park, holds the names of ICRF's generous benefactors who not only share the dream of making cancer history — but who also take proactive steps to make it happen.

Visit www.icrfonline.org/icrf-park to explore the park and learn more.

“Over the past four years, my wife and I have lost three dear friends to cancer. We are so impressed with the breakthrough research of ICRF scientists that we've decided to leave a legacy so future generations will not experience such loss. We recently updated our will, and I learned that the easiest way was to add ICRF as a beneficiary to my IRA account. All it took was an email to my stockbroker! It feels good knowing that we will be helping humankind even when we are no longer here.”

— **Jerry Silber**
Vice Chairman,
ICRF Connecticut Chapter

For more information about planned giving or ICRF Park naming opportunities, please call:
212-969-9800,
or email info@icrfonline.org.

Your contribution can help save lives!

Make a meaningful impact on cancer research by funding an ICRF grant in your name or in honor of a loved one. A designated grant can be made at every giving level.

Named Scientific Grant Opportunities:

Research Professorship Grant

(\$550,000 over a five-year period)
Awarded to senior scientists who have made outstanding contributions to cancer research.

Project Grants

(\$198,000 over a three-year period)
Awarded to established investigators working on a specific cancer research project.

Acceleration Grants

(\$154,000 over a two-year period)
Awarded to investigators proposing highly innovative approaches advancing cancer biology and therapeutics

Clinical Research Career Development Awards

(\$148,500 over a three-year period)
Awarded to promising oncologists to conduct clinical research projects early in their career.

Research Career Development Awards

(\$148,500 over a three-year period)
Awarded to promising investigators to conduct laboratory research projects early in their career.

Postdoctoral Fellowships

(\$99,000 over a three-year period)
Awarded to new MDs and PhDs to apprentice with senior investigators.

Collaborative Funding Awards

(\$495,000 over a three-year period)
Awarded to Israeli scientists working collaboratively with scientists at a North American institution.

Special Funding Initiatives

(Minimum of \$550,000 over a three-year period)
Awarded to investigators conducting cancer research in response to a donor-initiated proposal approved by ICRF's International Scientific Council.

International Board of Trustees 2021

President

David Abramson

Chair

Bryna Goldberg

Vice-Chairman

Rob Densen

First Vice-President

Joel Pelofsky

Vice Presidents

Arnold M. Baskies, MD

Charles Ben Dayan

Jeffrey Bernstein

Treasurer

Richard Edelheit

Secretary

Cynthia Perl

Executive Committee Members

Richard Lipkin

Nancy Maizels, PhD

Charles Serlin

Trustees

Robert Bard

Bruce Barron

Alan Berk

Jeffrey Bly

Benjamin Bonavida, PhD

Louis Brause

Michelle Chreine

Steven B. Cohen

Marsha Deakter

Jordanna Feifer

Vera Finkelstein

Bonnie E. Fish

Paul T. Fox

Leslie Freedman, PhD

S. Donald Friedman ♦

Tamir Gilat

Brad Goldhar

Kenneth E. Goodman

Gary I. Grad, MD

Robert Greene

Maryanne Greenfield

Lesley Heller

Samuel Herzfeld

Yashar Hirshaut, MD

Mark A. Israel, MD

Ian Kady

Beth Kaplan

Barbara Kasell

Susan Matteson King

Michelle Makori

David Malkin, MD

Len Mark

Patrick Mundt

Lisa Oved

Tom Peled

Gereld Soff, MD

Sidney J. Winawer, MD ♦

Presidents Emeritus

Rob Densen

Harriet Elisofon

Brad Goldhar

Yashar Hirshaut, MD

Harvey Kaylie*

Daniel G. Miller, MD*

Theodore T. Miller, MD

Chairs Emeritus

S. Donald Friedman ♦

Kenneth E. Goodman

Yashar Hirshaut, MD

Michael Rosenfelt

Leah Susskind*

Eve Wald*

Honorary Board Members

Evelyn Bienenfeld

Benjamin Brafman

Lynda Brafman

Harriet Elisofon

Maralyn Friedman

Faith G. Miller

Steven T. Rosen, MD

Michael Rosenfelt

Judith Sherman

Michel Steinberger

National Executive Director

Beryl P. Chernov

* Deceased

♦ Charter Board Member

Chapter Information

International Executive and New York Regional Offices

52 Vanderbilt Avenue

Suite 1510

New York, NY 10017

212-969-9800

info@icrfonline.org

Chicago

1 Northfield Plaza, Suite 235

Northfield, IL 60093

847-441-1824

chicagoteam@icrfonline.org

Connecticut Area

7 Lumanor Drive

Stamford, CT 06903

203-321-1006

ct@icrfonline.org

Los Angeles

info@icrfonline.org

Montreal

1310 Greene Avenue, Suite 710

Westmount, Quebec H3Z 2B2

514-481-2723

info@icrfmontreal.org

www.icrfmontreal.org

Toronto

1600 Steeles Avenue West, Suite 227

Concord, Ontario L4K 4M2

416-440-7780

research@icrf.ca

www.icrf.ca

Israel

26A Habarzel Street

Tel Aviv 6971037

+972-33806090

contact@icrf.org.il

www.icrf.org.il





Israel
Cancer
Research
Fund

Donate Online:
icrfonline.org/support

Donate Via Mail:
Israel Cancer Research Fund
P.O. Box 36
Hartsdale, NY 10530

Contact Us:
212-969-9800
info@icrfonline.org

Visit Our Website:
icrfonline.org

Follow Us On Social Media:
[@ICRFONLINE](https://www.instagram.com/ICRFONLINE)



Other Ways To Give:

Support ICRF While You Shop With AmazonSmile

Generate donations for ICRF while you shop through AmazonSmile at no cost to you. To participate, simply start shopping at Amazon using icrfonline.org/amazonmile to get to the site or turn AmazonSmile on in the Amazon app (iOS or Android) and select Israel Cancer Research Fund as your nonprofit of choice.



Double The Donation

Double the impact of your donation with a matching gift from your employer. Many employers match employee donations to ICRF and it only takes a few seconds to check if yours is one of them by visiting doublethedonation.com/icrf.



Tax ID (EIN): 51-0181215

Platinum
Transparency
2022

Candid.

Formerly GuideStar Platinum
Seal of Transparency